![Essential Information & Key Facts | [Topic of Article] - News Directory 3](https://blog.needymeds.org/wp-content/uploads/2025/06/image-1024x683.png "Essential Information & Key Facts | [Topic of Article]")
Essential Information & Key Facts | [Topic of Article]
- Adakveo, or crizanlizumab-tmca, is a prescription infusion treatment designed to lessen the frequency of vaso-occlusive crises (VOCs) in those 16 and older battling sickle cell disease (SCD).
- The medication functions by targeting P-selectin, a molecule involved in blood cell clumping. By blocking this molecule, Adakveo helps to reduce cell adhesion and inflammation that contribute to...
- The complex manufacturing process of biologic medications contributes to Adakveo's expense.
Facing the challenge of high Adakveo cost? Our comprehensive guide offers essential information for sickle cell disease patients. Understand how this medication reduces vaso-occlusive crises, along with the financial hurdles of accessing it. We detail Novartis’ copay program and patient assistance options, specifically designed to alleviate the burden of treatment expenses. Uncover eligibility criteria and submission processes to secure vital support. Explore resources like NeedyMeds for additional program listings and guidance on sickle cell disease treatment and Adakveo coupons. News Directory 3 highlights key facts and makes it easier for you to find crucial aid. Discover what’s next for your treatment journey.
Navigating Adakveo Cost: Assistance for Sickle Cell Patients
Updated June 20, 2025
Adakveo, or crizanlizumab-tmca, is a prescription infusion treatment designed to lessen the frequency of vaso-occlusive crises (VOCs) in those 16 and older battling sickle cell disease (SCD). VOCs, also known as pain crises, happen when sickled red blood cells obstruct blood flow, triggering severe pain and other complications.
The medication functions by targeting P-selectin, a molecule involved in blood cell clumping. By blocking this molecule, Adakveo helps to reduce cell adhesion and inflammation that contribute to VOCs. Typically, it’s administered monthly after two initial loading doses. The cost of Adakveo, a biologic infusion, can be high, making cost-saving programs essential for many patients seeking Adakveo cost relief.
The complex manufacturing process of biologic medications contributes to Adakveo’s expense. While no biosimilars are currently approved, Novartis provides programs to help with out-of-pocket expenses. Those with commercial insurance may be eligible for the Novartis Oncology Worldwide Co-pay Program, possibly lowering their cost to $25 per prescription, with up to $15,000 in annual coverage. Patients must present their copay card with their insurance at participating pharmacies.
For those uninsured, underinsured, or denied coverage, the Novartis Patient Assistance Foundation (NPAF) may offer free medication. Applicants must submit an application with proof of income and U.S. residency. A healthcare provider also needs to confirm the medical necessity of Adakveo. If approved, medication is provided at no cost for a specific period, with the option to reapply.
What’s next
Individuals seeking sickle cell disease treatment options and financial assistance can explore resources like NeedyMeds, which offers tools and program listings. Their helpline is also available at 800-503-6897 for personalized guidance on Adakveo coupons and other support.